Inicio>>Signaling Pathways>> Proteases>> Ser/Thr Protease>>PF-06446846 hydrochloride

PF-06446846 hydrochloride

Catalog No.GC38028

El clorhidrato de PF-06446846 es un inhibidor altamente selectivo y activo por vÍa oral de la traducciÓn de la proproteÍna convertasa subtilisina/kexina tipo 9 (PCSK9).

Products are for research use only. Not for human use. We do not sell to patients.

PF-06446846 hydrochloride Chemical Structure

Cas No.: 1632250-50-0

Tamaño Precio Disponibilidad Cantidad
1mg
92,00 $
Disponible
5mg
255,00 $
Disponible
10mg
408,00 $
Disponible
25mg
663,00 $
Disponible
50mg
1.224,00 $
Disponible
100mg
2.141,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com


Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PF-06446846 hydrochloride is an orally active and highly selective inhibitor of translation of Proprotein convertase subtilisin/kexin type 9 (PCSK9). PF-06446846 hydrochloride inhibits PCSK9 by inducing the ribosome to stall around codon 34[1].

PF-06446846 inhibits the secretion of PCSK9 by Huh7 cells with an IC50 of 0.3 μM[1].

PF-06446846 (oral gavage; 5-50 mg/kg/day for 14 days) lowers plasma PCSK9 in a dose-dependent manner and lowers total cholesterol levels[1]. Animal Model: Male Sprague-Dawley (Crl:CD [SD] rats, 6-8 wk old at initiation of dosing)[1]

[1]. Lintner NG, et al. Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. PLoS Biol. 2017 Mar 21;15(3):e2001882.

Reseñas

Review for PF-06446846 hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 33 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PF-06446846 hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.